- Country: USA
- Summary: Notice of Intent to Sole Source to Cerus Corporation for Intercept Platelet Processing Sets
- UST Ref No: 121893769
- Deadline: 11 Jul 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: 25-007944
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
Notice of Intent to Sole Source to Cerus Corporation for Intercept Platelet Processing Sets
Product Service Code: 6640 NAICS Code: 334516 Place of Performance: Bethesda, MD 20892 USA Purchase Order Number: 25-007944Description
This is a Notice of Intent and NOT a request for quotation. No solicitation will be issued, and quotations will not be requested.
The National Institutes of Health (NIH) intends to award a firm fixed-price purchase order on a sole source basis to Cerus Corporation, located at 1220 Concord Avenue Suite 600, Concord, California 94520-4906, for the purchase of Intercept Platelet Processing Sets (dual storage containers). Eight cases will be shipped monthly, starting July 15, 2025, through September 30, 2025.
The Transfusion Services Laboratory (TSL) provides 24/7 support to patients requiring blood transfusions as part of NIH protocols at the Clinical Center (CC). Conditions such as anemia and thrombocytopenia, common side effects of treatments including transplantation, sickle cell disease, and myelodysplastic syndromes, necessitate platelet transfusions.
This procurement is to obtain specific kits used in the pathogen reduction process. Pathogen Reduction Technology reduces the risk of transfusion-transmitted infections, including sepsis and transfusion-associated graft-versus-host disease, by inactivating pathogens and leukocyte contaminants in platelet components. This process is vital to protecting vulnerable patient populations receiving platelet transfusions at the CC.
The contract will cover the base period from June 1, 2025, through September 30, 2025.
Items Requested:
Quantity
Catalog #
Description
768 kits
INT2540B
INTERCEPT Platelet Processing Set with Dual Storage Containers (Semi-Integrated Set)
Cerus Corporation is the sole manufacturer of these Intercept Platelet Processing Sets, which are essential to rendering blood products safe for transfusion by reducing... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINNotice of Intent to Sole Source to Cerus Corporation for Intercept Platelet Processing Sets - USA Tender
The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | NATIONAL INSTITUTES OF HEALTH, a Government sector organization in USA, has announced a new tender for Notice of Intent to Sole Source to Cerus Corporation for Intercept Platelet Processing Sets. This tender is published on USARFP under UST Ref No: 121893769 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-07-11.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
